Katsurada N, Tachihara M, Hatakeyama Y, et al. - Whether the use of CBDCA (carboplatin) plus nab-PTX (nanoparticle albumin-bound paclitaxel) as adjuvant chemotherapy for non-small cell lung cancer (NSCLC) is feasible, was determined in this prospective, single-center, Phase II study. Participants were patients having fully resected stage II or III NSCLC, an Eastern Cooperative Oncology Group performance status of 0– 1 and adequate kidney function. Patients were administered four cycles of postoperative adjuvant chemotherapy with CBDCA (AUC = 5 mg/mL/min, on day 1) and nab-PTX (100 mg/m², on days 1, 8, and 15) every 4 weeks within 8 weeks post-surgery. The completion rate of chemotherapy was assessed as the primary endpoint. Neutropenia and anemia were documented as the most common grade 3 or 4 adverse events. For the four cycles, the completion rate was 63.2%. Two-year relapse-free survival of 56.8% was reported. In this study, non-attainment of treatment feasibility by the observed completion rate for CBDCA plus nab-PTX was reported when CBDCA plus nab-PTX was used as adjuvant chemotherapy for CDDP (cisplatin)-unfit NSCLC patients.